Evidence map›Paper›PMID 32202299›Full record

ArticleClinical science (London, England : 1979)2020

Renal functional effects of the highly selective AT2R agonist, β-Pro7 Ang III, in normotensive rats.

Lucinda M Hilliard Krause, Brandon A Kemp, Amanda Suan Jui Tan, Emma S Jones, Mark P Del Borgo, Marie-Isabel Aguilar, Kate M Denton, Robert M Carey, Robert E Widdop

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Clinical science (London, England : 1979), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The Angiotensin ATPharmacological reviews · 2022
    Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Lucinda M Hilliard KrauseDepartment of Physiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Brandon A KempDivision of Endocrinology and Metabolism, Department of Medicine University of Virginia School of Medicine, Charlottesville VA, U.S.A.
Amanda Suan Jui TanDepartment of Physiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Emma S JonesDepartment of Pharmacology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Mark P Del BorgoDepartment of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Marie-Isabel AguilarDepartment of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Kate M DentonDepartment of Physiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Robert M CareyDivision of Endocrinology and Metabolism, Department of Medicine University of Virginia School of Medicine, Charlottesville VA, U.S.A.
Robert E WiddopDepartment of Pharmacology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Australian Regenerative Medicine Institute · AUUniversity of Virginia · US

Funding

Renal AT2 Receptors in HypertensionR01HL128189 · NHLBI · UNIVERSITY OF VIRGINIA · PI KELLER, SUSANNA R · 2016 to 2024
$5.0M
NHLBI NIH HHS R01 HL128189
6 · The paper itself

Abstract

Recently, we designed a group of peptides by sequential substitution of the naturally occurring α-amino acid throughout the Ang III peptide sequence with the corresponding β-amino acid. β-Amino acid substitution at the proline residue of Ang III (β-Pro7-Ang III) resulted in a highly selective AT2R ligand, demonstrating remarkable selectivity for the AT2R in both binding and functional studies. To provide additional functional evidence for the suitability of β-Pro7 Ang III as a novel AT2R agonist, we tested effects of acute systemic administration of β-Pro7-Ang III on renal hemodynamic and excretory function in anesthetized normotensive male and female rats. We also compared the natriuretic effects of acute intrarenal administration of native Ang III and β-Pro7-Ang III in the presence of systemic AT1R blockade in anesthetized female rats to allow for the differentiation of systemic versus direct intrarenal natriuretic actions of β-Pro7-Ang III. In both male and female rats, acute systemic administration of β-Pro7-Ang III elicited renal vasodilatation and natriuresis. Notably, greater renal vasodilatory effects were observed in female versus male rats at the highest dose of β-Pro7-Ang III administered. Moreover, intra-renal administration of β-Pro7-Ang III produced significant natriuretic effects in female rats and, like Ang III, evoked AT2R translocation to the apical plasma membrane in renal proximal tubular cells. Taken together, our findings support the use of β-Pro7-Ang III as a novel AT2R agonist and experimental tool for exploring AT2R function and its potential as a therapeutic target. Furthermore, our findings provide further evidence of a sex-specific influence of AT2R stimulation on renal function.

Indexed as

Angiotensin IIIAnimalsFemaleKidneyMaleNatriuresisRats, Sprague-DawleyReceptor, Angiotensin, Type 2Renal CirculationRenin-Angiotensin SystemSex FactorsSignal TransductionVasodilationAgtr2 protein, ratAngiotensin IIIangiotensin III, beta-Pro(7)-Receptor, Angiotensin, Type 2angiotensin IIIAT2 receptor agonistkidneynatriuresisvasodilation

Identifiers

PMID32202299
PMCPMC7158249
OpenAlexW3012656501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.